Hologic (NASDAQ:HOLX) Updates Q1 2025 Earnings Guidance

Hologic (NASDAQ:HOLX) updated its first quarter 2025 earnings guidance on Monday. The company provided earnings per share guidance of 1.000-1.030 for the period, compared to the consensus earnings per share estimate of 1.030. The company issued revenue guidance of $1.0 billion-$1.0 billion, compared to the consensus revenue estimate of $1.0 billion. Hologic also updated its FY 2025 guidance to 4.250-4.350 EPS.

Analysts Set New Price Targets

HOLX has been the subject of several research reports. Royal Bank of Canada boosted their price target on Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a research report on Tuesday. Mizuho increased their price objective on Hologic from $85.00 to $90.00 and gave the company an “outperform” rating in a report on Friday, October 4th. JPMorgan Chase & Co. increased their price objective on Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research report on Tuesday. Citigroup cut Hologic from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $95.00 to $85.00 in a report on Tuesday, October 1st. Finally, Stephens reaffirmed an “overweight” rating and issued a $92.00 price objective on shares of Hologic in a research report on Tuesday, July 30th. Five analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $88.00.

Hologic Stock Down 4.8 %

Shares of NASDAQ:HOLX traded down $4.01 during midday trading on Tuesday, reaching $79.71. The company had a trading volume of 1,370,348 shares, compared to its average volume of 1,581,496. Hologic has a 1-year low of $66.93 and a 1-year high of $84.67. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. The stock has a market cap of $18.51 billion, a PE ratio of 27.10, a P/E/G ratio of 2.98 and a beta of 0.98. The business’s 50 day moving average price is $81.06 and its 200 day moving average price is $78.08.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.01. The company had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The business’s revenue was up 4.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.89 earnings per share. Research analysts forecast that Hologic will post 4.09 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.